Netarsudil 0.02%滴眼液预防糖皮质激素所致高眼压的随机双盲试验
这项前瞻性随机临床试验纳入120名受试者及71只对侧眼,在角膜移植术后使用netarsudil或安慰剂每日一次共9个月,同时使用泼尼松龙醋酸酯1%滴眼液。
要点
- Netarsudil组16%因眼部刺激提前退出。
核心结论
- Netarsudil 0.02%滴眼液预防性使用未能显著降低角膜移植术后糖皮质激素所致眼压升高的风险。
研究设计与样本
- 前瞻性随机临床试验,120名受试者随机接受netarsudil(超说明书使用)或安慰剂每日一次共9个月,71只对侧眼分配至相反治疗组。
主要发现
- netarsudil组15眼(16%)因眼部刺激提前退出。
关键数值与推荐
- 眼压升高定义为眼压≥24 mm Hg或较基线升高≥10 mm Hg。
- 受试者同时使用泼尼松龙醋酸酯1%滴眼液:每日4次共3个月,每日3次共1个月,每日2次共1个月,每日1次共4个月。
临床怎么用
- 对于角膜移植术后需长期使用糖皮质激素的患者,netarsudil预防眼压升高的证据尚不充分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess whether prophylactic use of netarsudil 0.02% ophthalmic solution reduces the risk of intraocular pressure (IOP) elevation associated with prolonged use of topical corticosteroids to prevent cornea transplantation rejection. DESIGN: Prospective, randomized clinical trial. METHODS: In this study, 120 subjects were randomized to use netarsudil (off-label) or placebo once daily for 9 months after Descemet membrane endothelial keratoplasty, and 71 fellow eyes were enrolled and assigned to the opposite treatment arm. Participants concurrently used topical prednisolone acetate 1% 4× daily for 3 months, 3× daily for a month, twice daily for a month, and once daily for 4 months. The main outcome was IOP elevation (defined as IOP ≥24 mm Hg or an increase of ≥10 mm Hg over baseline) assessed by Kaplan-Meier and proportional hazards analyses, taking loss to follow-up into consideration. RESULTS: Overall, 95 eyes were assigned to netarsudil and 96 to placebo; 15 eyes (16%) were withdrawn early from the netarsudil arm because of ocular irritation. The rate of IOP elevation was 14% with netarsudil and 21% with placebo (relative risk: 0.6; 95% confidence interval: 0.3-1.3; P = .23). IOP was >30 mm Hg in 7.8% assigned to netarsudil versus 7.4% assigned to placebo (P = .84). Median 6-month central endothelial cell loss was 31% versus 29% with netarsudil versus placebo, respectively (P = .49). CONCLUSIONS: Netarsudil did not produce a statistically significant reduction in the risk of steroid-induced IOP elevation after corneal transplantation relative to placebo.
引用
- Price MO, Feng MT, Price FW, et al. Randomized, Double-Masked Trial of Netarsudil 0.02% Ophthalmic Solution for Prevention of Corticosteroid-Induced Ocular Hypertension. Am J Ophthalmol. 2020. PMID: 33045216. doi:10.1016/j.ajo.2020.09.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。